Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging

Journal of the National Cancer Institute

Volumn 105, Issue 17, 2013, Pages 1314-1321

  Saadatmand, Sepideh ^b   Tilanus Linthorst, Madeleine M A ^a   Rutgers, Emiel J T ^b   Hoogerbrugge, Nicoline ^b   Oosterwijk, Jan C ^b   Tollenaar, Rob A E M ^b   Hooning, Maartje ^b   Loo, Claudette E ^b   Obdeijn, Inge Marie ^b   Heijnsdijk, Eveline A M ^b   De Koning, Harry J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST EXAMINATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FAMILY HISTORY; FEMALE; HEALTH CARE COST; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FAMILY; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASS SCREENING; MEDICAL HISTORY TAKING; MIDDLE AGED; MUTATION; NETHERLANDS; PALPATION; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84884498002     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt203     Document Type: Article

References (44)

1. de Boer M, van Dijck JA, Bult P, et al. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst. 2010;102(6):410-425.
2. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1-and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43(5):867-876.
3. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792.
4. de Koning HJ. Mammographic screening: evidence from randomised controlled trials. Ann Oncol. 2003;14(8):1185-1189.
5. Margolin S, Johansson H, Rutqvist LE, et al. Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County. Fam Cancer. 2006;5(4):309-321.
6. Brandt A, Bermejo JL, Sundquist J, et al. Age of onset in familial breast cancer as background data for medical surveillance. Br J Cancer. 2010;102(1):42-47.
7. FH Collaborative Teams. Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. Lancet Oncol. 2010;11(12):1127-1134.
8. Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, et al. Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer. 2000;36(4):514-519.
9. Checka CM, Chun JE, Schnabel FR, et al. The relationship of mammographic density and age: implications for breast cancer screening. Am J Roentgenol. 2012;198(3):W292-W295.
10. Zonderland HM, Coerkamp EG, Hermans J, et al. Diagnosis of breast cancer: contribution of US as an adjunct to mammography. Radiology. 1999;213(2):413-422.
11. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227-236.
12. Kerlikowske K. The mammogram that cried Wolfe. N Engl J Med. 2007;356(3):297-300.
13. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23(33):8469-8476.
14. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365(9473):1769-1778.
15. Rijnsburger AJ, Obdeijn IM, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol. 2010;28(36):5265- 5273.
16. Griebsch I, Brown J, Boggis C, et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer. 2006;95(7):801-810.
17. Lee JM, McMahon PM, Kong CY, et al. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. Radiology. 2010;254(3):793-800.
18. Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006;295(20):2374-2384
19. National Institute for Health and Clinical Excellence (NICE). Familial Breast Cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. NICE Clinical Guideline 164 http://www.nice.org.uk/ nicemedia/live/14188/64202/64202.pdf. Accessed 07-15-2013.
20. Mann RM, Kuhl CK, Kinkel K, et al. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol. 2008;18(7): 1307-1318.
21. American College of Radiology (ACR). ACR Practice Guideline for the Performance of Contrastenhanced Magnetic Resonance Imaging (MRI) of the Breast. http://www.acr.org/~/media/ACR/Documents/PGTS/guidelines/MRI-Breast.pdf. Accessed July 15, 2013.
22. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75-89.
23. Nationaal Borstkanker Overleg Nederland (NABON). Richtlijn Mammacarcinoom (Breast Cancer National Guideline). http://oncoline.nl/richtlijn/doc/index.php? type=pda&richtlijn-id=828. Accessed July 8, 2013.
24. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73(3):643-651.
25. Kriege M, Brekelmans CT, Boetes C, et al. MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC). Fam Cancer. 2001;1(3-4):163-168.
26. Rijnsburger AJ, van Oortmarssen GJ, Boer R, et al. Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation. Int J Cancer. 2004;110(5):756-762.
27. National Evaluation Team for Breast Cancer Screening (NETB). National Evaluation of Breast Cancer Screening in the Netherlands-Eleventh Evaluation Report. Rotterdam: Department of Public Health, Erasmus MC; 2005.
28. Bjurstam N, Bjorneld L, Warwick J, et al. The Gothenburg Breast Screening Trial. Cancer. 2003;97(10):2387-2396.
29. Nystrom L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909-919.
30. Tabar L, Yen MF, Vitak B, et al. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003;361(9367):1405-1410.
31. de Gelder R, Bulliard JL, de Wolf C, et al. Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. Eur J Cancer. 2009;45(1):127-138.
32. Barton R, Ivey J. Nelder-Mead simplex modifications for simulation optimization. Manag Sci. 1996;42(7):954-973.
33. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296(13):716-721.
34. Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131(3):1061-1066.
35. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.
36. Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer. 2012;107(1):24-30.
37. Tilanus-Linthorst MM, Lingsma HF, Evans DG, et al. Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk. Int J Cancer. 2013;133(1):156-163.
38. Moore SG, Shenoy PJ, Fanucchi L, et al. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res. 2009;9(1):9.
39. Norman RP, Evans DG, Easton DF, et al. The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49. Eur J Health Econ. 2007;8(2):137-144.
40. Taneja C, Edelsberg J, Weycker D, et al. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol. 2009;6(3):171-179.
41. Jacobi CE, de Bock GH, Siegerink B, et al. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat. 2009;115(2):381-390.
42. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst. 2008;100(14):1037- 1041.
43. Obdeijn IM, Loo CE, Rijnsburger AJ, et al. Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition. Breast Cancer Res Treat. 2010;119(2):399-407.
44. Saadatmand S, Rutgers EJ, Tollenaar R, et al. Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial. BMC Cancer. 2012;12(1):440.